{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:07:17Z","timestamp":1789204037933,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jad.2017.04.072","type":"journal-article","created":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T11:46:00Z","timestamp":1493466360000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Dextromethorphan\/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial"],"prefix":"10.1016","volume":"218","author":[{"given":"James W.","family":"Murrough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Stade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehrish","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew D.","family":"Kiraly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laili","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan V.","family":"Iosifescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis S.","family":"Charney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2017.04.072_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jad.2017.04.072_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-4679(198807)44:4<499::AID-JCLP2270440404>3.0.CO;2-6","article-title":"Scale for suicide ideation: psychometric properties of a self-report version","volume":"44","author":"Beck","year":"1988","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.jad.2017.04.072_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2017.04.072_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress."},{"key":"10.1016\/j.jad.2017.04.072_bib5","first-page":"9","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Caddy","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jad.2017.04.072_bib6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.euroneuro.2014.09.001","article-title":"Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder","volume":"24","author":"Chen","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.04.072_bib7","first-page":"1","article-title":"An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in dementia: PRISM II results","author":"Doody","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2017.04.072_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000201934","article-title":"Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire","volume":"78","author":"Fava","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2017.04.072_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0028-3908(98)00007-0","article-title":"Structural determinants of the blocker binding site in glutamate and NMDA receptor channels","volume":"37","author":"Ferrer-Montiel","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2017.04.072_bib10","unstructured":"First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P). Biometrics Research, New York State Psychiatric Institute, New York."},{"key":"10.1016\/j.jad.2017.04.072_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib12","doi-asserted-by":"crossref","unstructured":"Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology-revised NIMH Psychopharmacology Research Branch, Washington, DC.","DOI":"10.1037\/e591322011-001"},{"key":"10.1016\/j.jad.2017.04.072_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jad.2017.04.072_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jphs.2014.07.001","article-title":"Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs","volume":"127","author":"Hayashi","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.jad.2017.04.072_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jad.2014.05.050","article-title":"The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS","volume":"167","author":"Kelly","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2017.04.072_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00788510","article-title":"Assessing impairment in patients with panic disorder: the Sheehan Disability Scale","volume":"27","author":"Leon","year":"1992","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.jad.2017.04.072_bib17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1017\/S0033291799008570","article-title":"The range of impaired functioning tool (LIFE-RIFT): a brief measure of functional impairment","volume":"29","author":"Leon","year":"1999","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.072_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/dmd.111.042200","article-title":"Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole","volume":"40","author":"Lutz","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jad.2017.04.072_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0006-3223(03)00117-3","article-title":"Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression","volume":"53","author":"Manji","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/da.20540","article-title":"Treatment-resistant depression: recent developments and future directions","volume":"25","author":"Mathew","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jad.2017.04.072_bib21","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/sj.npp.1301652","article-title":"Novel drugs and therapeutic targets for severe mood disorders","volume":"33","author":"Mathew","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2017.04.072_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib25","doi-asserted-by":"crossref","first-page":"e89985","DOI":"10.1371\/journal.pone.0089985","article-title":"Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan","volume":"9","author":"Nguyen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2017.04.072_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2015.03.024","article-title":"Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice","volume":"295","author":"Nguyen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jad.2017.04.072_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","article-title":"Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders","volume":"159","author":"Nguyen","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2017.04.072_bib28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/mp.2015.92","article-title":"Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder","volume":"20","author":"Papakostas","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.brs.2016.03.010","article-title":"The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder","volume":"9","author":"Perera","year":"2016","journal-title":"Brain Stimul."},{"key":"10.1016\/j.jad.2017.04.072_bib30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jad.2017.04.072_bib31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0091270004269521","article-title":"Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers","volume":"44","author":"Pope","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2017.04.072_bib32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The inventory of depressive symptomatology (IDS): psychometric properties","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2017.04.072_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 16","key":"10.1016\/j.jad.2017.04.072_bib36","first-page":"S10","article-title":"The definition and meaning of treatment-resistant depression","volume":"62","author":"Sackeim","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jad.2017.04.072_bib38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11530280-000000000-00000","article-title":"Therapeutic options for treatment-resistant depression","volume":"24","author":"Shelton","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2017.04.072_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjp.0705998","article-title":"The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan","volume":"144","author":"Shin","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2017.04.072_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neuint.2007.01.008","article-title":"Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats","volume":"50","author":"Shin","year":"2007","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jad.2017.04.072_bib42","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3171\/jns.1996.84.5.0860","article-title":"Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients","volume":"84","author":"Steinberg","year":"1996","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jad.2017.04.072_bib44","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2850.2011.01735.x","article-title":"Quality of life enjoyment and satisfaction questionnaire-short form for quality of life assessments in clinical practice: a psychometric study","volume":"18","author":"Stevanovic","year":"2011","journal-title":"J. Psychiatr. Ment. Health Nurs."},{"key":"10.1016\/j.jad.2017.04.072_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","article-title":"Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta(R)) clinical use","volume":"164","author":"Taylor","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2017.04.072_bib46","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2017.04.072_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.04.072_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2017.04.072_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","article-title":"A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder","volume":"207","author":"Werling","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jad.2017.04.072_bib50","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2017.04.072_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40265-014-0328-z","article-title":"Dextromethorphan\/quinidine: a review of its use in adults with pseudobulbar affect","volume":"75","author":"Yang","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2017.04.072_bib52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717301076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032717301076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:17:35Z","timestamp":1759022255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032717301076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":52,"alternative-id":["S0165032717301076"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2017.04.072","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dextromethorphan\/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2017.04.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}